Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M105,472Revenue $M18,676Net Margin (%)25.7Z-Score2.3
Enterprise Value $M112,612EPS $6.6Operating Margin %31.6F-Score4
P/E(ttm))21.4Cash Flow Per Share $6.7Pre-tax Margin (%)28.2Higher ROA y-yN
Price/Book4.410-y EBITDA Growth Rate %11.0Quick Ratio4.0Cash flow > EarningsY
Price/Sales5.55-y EBITDA Growth Rate %8.7Current Ratio4.4Lower Leverage y-yY
Price/Cash Flow13.3y-y EBITDA Growth Rate %20.5ROA % (ttm)8.0Higher Current Ratio y-yN
Dividend Yield %1.7Insider Buy (3m)1ROE % (ttm)22.5Less Shares Outstanding y-yN
Payout Ratio %33.0Shares Outstanding M757ROI % (ttm)8.2Gross Margin Increase y-yN

Gurus Latest Trades with AMGN

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
AMGNDaniel Loeb 2014-06-30 Buy 0.65%$110.29 - $126.07
($115.72)
$ 141.3822%New holding, 450000 sh.450,000
AMGNJoel Greenblatt 2014-06-30 Buy 0.02%$110.29 - $126.07
($115.72)
$ 141.3822%New holding, 9938 sh.9,938
AMGNMario Gabelli 2014-06-30 Add0.02%$110.29 - $126.07
($115.72)
$ 141.3822%Add 85.28%60,335
AMGNJohn Hussman 2014-06-30 Reduce-0.93%$110.29 - $126.07
($115.72)
$ 141.3822%Reduce -66.67%50,000
AMGNMario Gabelli 2014-03-31 Add0.01%$113.48 - $127.47
($121.04)
$ 141.3817%Add 37.87%32,565
AMGNDodge & Cox 2014-03-31 Reduce$113.48 - $127.47
($121.04)
$ 141.3817%Reduce -22.59%105,757
AMGNPRIMECAP Management 2014-03-31 Reduce-0.46%$113.48 - $127.47
($121.04)
$ 141.3817%Reduce -9.42%32,161,744
AMGNVanguard Health Care Fund 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 141.3817%Reduce -6.4%8,213,855
AMGNJohn Hussman 2014-03-31 Reduce-0.2%$113.48 - $127.47
($120.95)
$ 141.3817%Reduce -14.29%150,000
AMGNJoel Greenblatt 2014-03-31 Sold Out -0.06%$113.48 - $127.47
($121.04)
$ 141.3817%Sold Out0
AMGNRay Dalio 2014-03-31 Sold Out -0.01%$113.48 - $127.47
($121.04)
$ 141.3817%Sold Out0
AMGNJoel Greenblatt 2013-12-31 Buy 0.06%$106.28 - $118.688
($113.73)
$ 141.3824%New holding, 23170 sh.23,170
AMGNRay Dalio 2013-12-31 Buy 0.01%$106.28 - $118.688
($113.73)
$ 141.3824%New holding, 7513 sh.7,513
AMGNVanguard Health Care Fund 2013-12-31 Reduce-0.76%$106.28 - $118.688
($113.73)
$ 141.3824%Reduce -18.43%8,775,155
AMGNJohn Hussman 2013-12-31 Reduce-0.45%$106.28 - $118.688
($113.73)
$ 141.3824%Reduce -30%175,000
AMGNJohn Hussman 2013-09-30 Add0.3%$95.81 - $117.521
($108.55)
$ 141.3830%Add 25%250,000
AMGNMario Gabelli 2013-09-30 Add$95.81 - $117.521
($108.55)
$ 141.3830%Add 26.95%22,420
AMGNPRIMECAP Management 2013-09-30 Reduce-0.22%$95.81 - $117.521
($108.55)
$ 141.3830%Reduce -4.11%35,812,225
AMGNRay Dalio 2013-09-30 Sold Out -0.07%$95.81 - $117.521
($108.55)
$ 141.3830%Sold Out0
AMGNDodge & Cox 2013-09-30 Reduce-0.01%$95.81 - $117.521
($108.55)
$ 141.3830%Reduce -38.73%160,052
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

AMGN is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
AMGN Joel Greenblatt 2014-06-309,93800.02New Buy
AMGN Daniel Loeb 2014-06-30450,0000.060.65New Buy
AMGN Mario Gabelli 2014-06-3060,3350.010.04+85.28%
AMGN PRIMECAP Management 2014-06-3031,853,8444.214.1-0.96%
AMGN Vanguard Health Care Fund 2014-06-308,049,4551.062.5-2%
AMGN Dodge & Cox 2014-06-3085,8570.010.01-18.82%
AMGN John Hussman 2014-06-3050,0000.010.45-66.67%
Premium Most recent portfolio changes are included for Premium Members only!


AMGN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patton Cynthia MSVP & CCO 2014-08-05Sell2,644$127.9710.48view
Harper Sean EEVP, Research & Development 2014-08-05Sell14,000$127.2911.07view
Dittrich Thomas J.W.VP, Finance & CAO 2014-05-21Sell4,130$112.8325.3view
Bradway Robert AChairman, CEO and President 2014-05-12Buy894$111.7726.49view
Michael A KellyActing CFO 2014-04-28Sell2,065$110.4528view
de Carbonnel FrancoisDirector 2014-03-06Sell1,000$126.6911.6view
HENDERSON REBECCA MDirector 2014-02-13Sell20,000$123.5314.45view
AMGEN INC10% Owner 2013-12-17Buy272,142$71919.71view
Balachandran MadhavanEVP, Operations 2013-09-04Sell18,000$112.7625.38view
BALTIMORE DAVIDDirector 2013-08-28Sell4,582$109.6628.93view

Press Releases about AMGN :

    Quarterly/Annual Reports about AMGN:

    News about AMGN:

    Articles On GuruFocus.com
    Amgen: Stronger Drug Portfolio with Acquisition Sep 22 2014 
    Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
    Weekly 52-Week Highs Highlight: ABT, SWK, LMT, AMGN Sep 13 2014 
    After Reaching All-Time Highs, How Can Gilead Sciences Continue growing? Aug 27 2014 
    Gulf Resources (GURE) Impressive Performance, Amgen (AMGN) and AstraZeneca (AZN) Positive Data From May 11 2014 
    Amgen Inc: As Good as It Gets? Feb 20 2014 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Mario Gabelli Comments on Amgen Inc. Jan 06 2014 
    The Gabelli Asset Fund Shareholder Commentary - Third Quarter Jan 06 2014 
    38 Stocks with Higher Dividends Dec 23 2013 

    More From Our Partners
    Amgen, Inc. Showing Strong Performance Despite Low Beta Sep 30 2014 - BENZINGA

    More From Other Websites
    Amgen, Inc. Showing Strong Performance Despite Low Beta Sep 30 2014
    Amgen Inc Conference Call on Kyprolis at ESMO scheduled for 4:00 pm ET today Sep 29 2014
    AMGN, ACT And GILD, Pushing Drugs Industry Downward Sep 29 2014
    [video] Biotech selloff: What to buy Sep 25 2014
    Biotech selloff: What to buy Sep 25 2014
    Zacks Rank #1 Additions for Thursday Sep 25 2014
    Amgen to Host Summary Webcast of Kyprolis® (carfilzomib) for Injection Data Presented at The... Sep 24 2014
    Acorda To Buy Civitas, Gains Parkinson's Disease Drug Sep 24 2014
    For Second Act, Acorda Drops $525 Million On Inhaled Parkinson's Drug Sep 24 2014
    ESMO 2014 to Feature New Oncology Data from Across Bayer Franchise Sep 24 2014
    Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab Sep 22 2014
    Today's Market Thorns, Roses, and All Time Highs... Sep 19 2014
    Today's Market Thorns, Roses and All Time Highs... Sep 18 2014
    UCB-Amgen Reveals Positive Data on Romosozumab for PMO Sep 17 2014
    The Market's Thorns, Roses, and All Time Highs... Sep 17 2014
    Amgen, Inc. Poised To Break Higher Sep 17 2014
    Biotech still place to be: Pro Sep 15 2014
    [video] Biotech still place to be: Pro Sep 15 2014
    Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of... Sep 15 2014
    New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued... Sep 15 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK